Kymera Therapeutics (KYMR) PT Raised to $34 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Price: $136.25 --0%
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 20 | Down: 37 | New: 6
Join SI Premium – FREE
Morgan Stanley analyst Vikram Purohit raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $34.00 (from $33.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Kymera Therapeutics (KYMR) PT Raised to $170 at Barclays
- McDonald's (MCD) PT Raised to $307 at KeyBanc
- Dutch Bros Inc. (BROS) PT Lowered to $52 at KeyBanc
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
